Literature DB >> 17970962

Polymorphism in the cholesteryl ester transfer protein gene and the risk of early onset myocardial infarction among cigarette smokers.

Ilan Goldenberg1, Arthur J Moss, Robert Block, Daniel Ryan, James P Corsetti, Scott McNitt, Shirley W Eberly, Wojciech Zareba.   

Abstract

BACKGROUND: Cigarette smoking and the common B1 allele of the TaqIB polymorphism have both been reported to be associated with increased cholesteryl ester transfer protein (CETP) activity and altered lipoprotein levels. Thus, it is possible that the combined presence of these two respective environmental and genetic factors may enhance cardiovascular risk. We hypothesized that susceptibility to early onset myocardial infarction (MI) among cigarette smokers may be related to the presence of TaqIB polymorphism in the CETP gene.
METHODS: The age at onset of a first MI among current (n = 199), past (n = 345), and never (n = 270) smokers was related to the presence of the TaqIB1 and B2 alleles in a cohort of 814 first MI patients.
RESULTS: Multivariate regression analysis demonstrated that cigarette smoking was associated with a significant increase in the risk for early onset MI only among carriers of the TaqIB1 allele: current smokers with the B1B1 and B1B2 genotypes displayed a respective 9.4 (P < 0.001) and 8.4 (P < 0.001) year reduction in the age at onset of a first MI compared with never smokers, and past smokers with these genotypes exhibited a respective 3.8 (P = 0.003) and 3.7 (P = 0.01) year reduction. By contrast, current and past smoking was not associated with a significant increase in the risk for early onset MI among B2B2 homozygotes (3.0 [P = 0.28] and 0.2 [P = 0.93] year reduction, respectively). The smoking x genotype interaction was statistically significant (P = 0.04).
CONCLUSIONS: The current findings suggest that genetic factors may modify susceptibility to early onset MI among cigarette smokers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17970962      PMCID: PMC6932528          DOI: 10.1111/j.1542-474X.2007.00186.x

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  29 in total

1.  A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men.

Authors:  Simin Liu; Christian Schmitz; Meir J Stampfer; Frank Sacks; Charles H Hennekens; Klaus Lindpaintner; Paul M Ridker; Simm Liu
Journal:  Atherosclerosis       Date:  2002-04       Impact factor: 5.162

2.  Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study.

Authors:  J M Ordovas; L A Cupples; D Corella; J D Otvos; D Osgood; A Martinez; C Lahoz; O Coltell; P W Wilson; E J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-05       Impact factor: 8.311

3.  Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.

Authors:  S M Boekholdt; F M Sacks; J W Jukema; J Shepherd; D J Freeman; A D McMahon; F Cambien; V Nicaud; G J de Grooth; P J Talmud; S E Humphries; G J Miller; G Eiriksdottir; V Gudnason; H Kauma; S Kakko; M J Savolainen; M Arca; A Montali; S Liu; H J Lanz; A H Zwinderman; J A Kuivenhoven; J J P Kastelein
Journal:  Circulation       Date:  2005-01-17       Impact factor: 29.690

4.  Relation of cigarette smoking to myocardial infarction in young women.

Authors:  D Slone; S Shapiro; L Rosenberg; D W Kaufman; S C Hartz; A C Rossi; P D Stolley; O S Miettinen
Journal:  N Engl J Med       Date:  1978-06-08       Impact factor: 91.245

5.  Facilitated nitration and oxidation of LDL in cigarette smokers.

Authors:  Y Yamaguchi; J Haginaka; S Morimoto; Y Fujioka; M Kunitomo
Journal:  Eur J Clin Invest       Date:  2005-03       Impact factor: 4.686

6.  Oxidants in cigarette smoke extract modify low-density lipoprotein in the plasma and facilitate atherogenesis in the aorta of Watanabe heritable hyperlipidemic rabbits.

Authors:  Y Yamaguchi; S Matsuno; S Kagota; J Haginaka; M Kunitomo
Journal:  Atherosclerosis       Date:  2001-05       Impact factor: 5.162

Review 7.  Smoking and gender.

Authors:  Chiara Bolego; Andrea Poli; Rodolfo Paoletti
Journal:  Cardiovasc Res       Date:  2002-02-15       Impact factor: 10.787

8.  DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels.

Authors:  I Kondo; K Berg; D Drayna; R Lawn
Journal:  Clin Genet       Date:  1989-01       Impact factor: 4.438

Review 9.  Plasma lipid transfer proteins.

Authors:  A Tall
Journal:  Annu Rev Biochem       Date:  1995       Impact factor: 23.643

10.  Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.

Authors:  Margaret E Brousseau; John J O'Connor; Jose M Ordovas; Dorothea Collins; James D Otvos; Tatyana Massov; Judith R McNamara; Hanna B Rubins; Sander J Robins; Ernst J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-07-01       Impact factor: 8.311

View more
  4 in total

1.  Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels.

Authors:  James P Corsetti; Dan Ryan; David L Rainwater; Arthur J Moss; Wojciech Zareba; Charles E Sparks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-20       Impact factor: 8.311

2.  The link between human and transgenic animal studies involving postprandial hypertriglyceridemia and CETP gene polymorphisms.

Authors:  Genovefa D Kolovou; Katherine K Anagnostopoulou; Dimitri P Mikhailidis
Journal:  Open Cardiovasc Med J       Date:  2009-06-11

3.  Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels.

Authors:  James P Corsetti; Peter Salzman; Dan Ryan; Arthur J Moss; Wojciech Zareba; Charles E Sparks
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

4.  Data in support of a central role of plasminogen activator inhibitor-2 polymorphism in recurrent cardiovascular disease risk in the setting of high HDL cholesterol and C-reactive protein using Bayesian network modeling.

Authors:  James P Corsetti; Peter Salzman; Dan Ryan; Arthur J Moss; Wojciech Zareba; Charles E Sparks
Journal:  Data Brief       Date:  2016-05-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.